PHENOTYPIC DETECTION OF AmpC β-LACTAMASE PRODUCTION IN GRAM NEGATIVE CLINICAL ISOLATES

NEETU GUPTA¹, SAVITA JADHAV²*, N.R. GANDHAM³, R. N. MISRA⁴, AISHWARYA VARMA^5
1Department of Microbiology Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeeth, Pune 411018
²Department of Microbiology Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeeth, Pune 411018
³Department of Microbiology Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeeth, Pune 411018
⁴Department of Microbiology Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeeth, Pune 411018
⁵Department of Microbiology Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeeth, Pune 411018
* Corresponding Author : patilsv78@gmail.com

Received : 15-12-2017     Accepted : 26-12-2017     Published : 30-01-2018
Volume : 10     Issue : 1       Pages : 997 - 1000
Int J Microbiol Res 10.1 (2018):997-1000
DOI : http://dx.doi.org/10.9735/0975-5276.10.1.997-1000

Keywords : Prevalence, AmpC β- lactamase, MDR isolates
Academic Editor : Daniel Cohen Goldemberg, Igbokwe Chris, Dr Mudit Chandra, Mara Lúcia Queiroz, Alcaide Moreno Elena
Conflict of Interest : None declared
Acknowledgements/Funding : Authors are thankful to Department of Microbiology. Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeeth, Pimpri Pune 411018
Author Contribution : All author equally contributed

Background: Detection of AmpC β-lactamase producing isolates is needed to provide the accurate and effective treatment to patient for their better outcome. In laboratories test can be performed by simple phenotypic screening and confirmation method. Objectives: To determine the prevalence of MDR isolates and AmpC β-lactamase producers from clinical samples. Materials and Methods: A total no. of 600 gram negative organisms included in the study from which 318 were MDR. All MDR isolates screened and confirmed for AmpC β-lactamase production by cefoxitin and Cefoxitin, cefoxitin-cloxacillin double disc synergy test respectively. For inducible AmpC β-lactamase production cefotaxime and cefoxitin discs were used. Blunting of zone of inhibition of cefotaxime placed adjacent to cefoxitin considered positive for inducible AmpC producer. Results: From total 600 gram negative organisms, 318 were MDR gram negative isolates. Out of 318 gram negative isolates, 281 showed positive AmpC β-lactamase screening test by cefoxitin resistance. Prevalence of AmpC β-lactamase producers was 42.70% from screening positive isolates. Interpretation and conclusion: Accurate detection of AmpC β-lactamase producers in laboratories and proper treatment of patient will help to control the spread of these pathogens and control of antibiotic resistance.

1. Polsfuss S., Bloemberg G.V., Giger J., Meyer V., Bottger E.C. and Hombach M. (2011) J Clin Microbiol., 49(8), 2798-803.
2. Satish P.N., Shripad P.S. and Santosh D. (2013) J Med Res Prac., 2(7), 179-90.
3. Jacoby G.A. (2009) Clin. Microbiol. Rev., 22(1), 161-82.
4. Mohamudha P.R., Harish B.N. and Parija S.C. (2012) Indian J Med Res., 114-9.
5. Mohamudha P.R., Harish B.N. and Parija S.C. (2010) Braz. J.Microbiol.,41, 596-602.
6. Kumar V., Sen M.R., Nigam C., Gahlot R. and Kumari S. (2012) Indian J Crit Care Med., 16(3), 136-40.
7. Oberoi L., Singh N., Sharma P. and Aggarwal A. (2013) J ClinDiagn Res., 7(1), 70-3.
8. Bush K. (2010) Critical Care, 14,1-8.
9. Manoharan A., Sugumar M., Kumar A., Jose H., Mathai D. and ICMR-ESBL study group (2012) Indian JMed Res., 359-64.
10. Clinical and Laboratory Standards Institute (2013) Performance standards for Antimicrobial susceptibility testing. In: Twenty-third informational supplement M100-S23. Wayne, PA, USA: CLSI.
11. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. (2012) Clin Microbiol Infect., 8, 268-81.
12. Kaur A., Gill A.K., Singh S., Kaur N., Mahajan A. and Mittal V. (2016) Int J Health Sci Res., 6(6), 83-9.
13. Laghawe A.R., Jaitly N.K. and Thombare V.R. (2012) J Pharm Biomed Sci., 20(07), 1-4.
14. Mohd Khari F.I., Karunakaran R., Rosli R., and Tay S.T. (2016) PLoS One., 11(3), 1-12.
15. Nagdeo N.V., Kaore N.M. and Thombare V.R. (2012) CHRON.YOUNG SCI. 3(4), 292-8
16. Afnuwa R.A., Odimegwu D.C., Iroha R.I. and Esimone C.O. (2011) Bosn J Basic Med Sci., 11 (2), 92-6.
17. Hemalatha V., Padma M., Sekar U., Vinodh T.M. and Arunkumar A.S. (2007) Indian J Med Res., 126, 220-3.
18. Khan M.N., Srivastava P., Chophi V. and Singh N.P. (2015) Int. Res. J. Medical Sci., 3(8),1-6.
19. Jadhav S., Misra R.N., Nageswari R., Ujagare M., Ghosh P., Angadi K., et al. (2012) Int J Microbiol Res., 4(6), 253-7.
20. Rajini E., Sherwal B.L. and Anuradha (2008) IJPD, 4(6) (2008-1-2008-2).
21. Manchanda V. and Singh N.P. (2003) India J Antimicrob Chemother., 51, 415–8.
22. Gupta N., Gandham N., Jadhav S. and Misra R.N. (2015) J Nat Biol Med., 6(1), 159-62.
23. Madhumati B., Leela R., Ranjini C.Y. and Rajendran R. (2015) Int. J. Curr. Microbiol. App. Sci., 4(9), 219-227.
24. Neha, Routray A. and Shenoy S. (2014) Int J Pharm Bio Sci., 5(3), 465 –72.